Drugs / RG-7603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01356173 | Jun 2011 → Dec 2012 | non-Hodgkin lymphoma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG-7603 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2331680 ↗ |
| Known as | GDC-0349 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01356173 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL2331680 ↗ |
| Modality | Small molecule | — CHEMBL2331680 ↗ |
| Route | Oral | “GDC-0349 administered once daily (QD), orally (PO)” NCT01356173 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL2331680 ↗ |